Introduction {#s1}
============

Intraductal papillary mucinous neoplasm (IPMN) is a substantial subclass of pancreatic pathology, representing 20-50% of cystic pancreatic neoplasms \[[@R01]-[@R03]\]. The incidence and subsequent resection of IPMN have increased over the last 20 years, partially explained by the increased utilization of high-resolution diagnostic imaging \[[@R04]\]. IPMN is thought to represent a precursor lesion to pancreatic adenocarcinoma due to its association with invasive carcinoma \[[@R05]\]. Due to the increased recognition of pancreatic cystic lesions, adequately stratifying patients based on their malignancy risk is increasingly important; particularly so, when deciding between surgical intervention and active surveillance.

Several pathologic variables have been implicated in the risk evaluation of malignancy for IPMN including branch duct vs. main duct involvement and presence or absence of a cystic mural nodule \[[@R06]-[@R08]\]. Four main histologic subtypes of IPMN have been described: gastric, intestinal, pancreaticobiliary and oncocytic. These subtypes differ in their prognosis and their risk for dysplasia and/or invasive carcinoma \[[@R9]-[@R11]\]. Mucin glycoprotein expression in IMPN epithelial cells within the cyst lining is routinely used to help characterize these IPMN subtypes by immunohistochemistry \[[@R12]\]. Although these biomarkers are useful in helping distinguish individual IPMN subtypes, this immunohistochemical assessment is often only possible after resection.

In an attempt to identify pancreatic cystic lesions with an increased risk of associated invasive adenocarcinoma, carcinoembryonic antigen (CEA) level has emerged over the last few decades as a tool to assess pancreatic cystic fluid pre-operatively. During the diagnostic workup for pancreatic cysts, CEA is often utilized to distinguish those pancreatic cystic lesions that are likely to be mucinous \[[@R13]-[@R16]\]. In addition to CEA being used to stratify mucinous vs. non-mucinous lesions, several studies have attempted to correlate pancreatic cyst fluid CEA level and the presence of invasive carcinoma, with discordant results \[[@R17], [@R18]\]. As it stands, the pathologic correlate of elevated CEA within cyst fluid remains unclear. Moreover, the relationship between CEA and IPMN subtypes has not been sufficiently assessed.

Therefore, the aims of this study were to correlate pre-operative cyst fluid CEA level with the histopathologic features and mucin glycoprotein expression of IPMN after pancreatic resection.

Materials and Methods {#s2}
=====================

The study was approved by appropriate institutional review board, and followed the ethical compliance with human study. Forty-five cases of pancreatic resection for IPMN between the years 2003 - 2014 were retrospectively reviewed. Pathologic variables of the resected IPMNs included in the analysis were: the subtype of IPMN, pathologic size of cystic lesion, pre-resection pancreatic cyst fluid CEA level (ng/mL), presence or absence of dysplasia (low or high grade), presence or absence of invasive carcinoma, and main duct or branch duct involvement. Pancreatic cyst fluid CEA was assessed by enzyme immunoassay (AccuCea Redpath Integrated Pathology, now Interpace Diagnostics). A cut-off for elevated CEA, indicating a most likely mucinous IPMN, was set at \> 192 ng/mL, per the test manufactures recommendations. Due to an insufficient number of cases with cyst fluid amylase measurements, amylase measurements were not included in the study.

Protein expression was assessed via immunohistochemistry (IHC) for circulating anti-mucin (MUC)1, MUC2, MUC5, MUC6, polyclonal CEA (CEA-P), and CDX2 on each case. IHC positivity for each marker was scored based on intensity of staining, from 0 (no staining) to 3+ (strong staining) ([Fig. 1](#F1){ref-type="fig"}). As a negative control, four cases of serous cystadenoma were stained for CEA-P. Immunohistochemical positivity was assessed within the following locations: intra-cystic secretions, luminal surface and cytoplasm of neoplastic epithelium and the adjacent non-lesional pancreatic tissues. Pathologic variables and IHC findings were compared to pre-operative pancreatic cyst CEA level. Descriptive statistics and bivariate correlation analysis were carried out using IBM SPSS (version 1.0.0-1058). In attempt to control for random variation, outliers were identified and removed when present at 1.5 interquartile ranges (IQRs) below the first quartile or above the third quartile.

![Luminal staining for CEA, assessed by immunohistochemistry and graded as 0 to 3+. (a) Luminal CEA: 1+ (× 200). (b) Luminal CEA: 2+ (× 200). (c) Luminal CEA: 3+ (× 200).](gr-12-185-g001){#F1}

Results {#s3}
=======

Descriptive statistics of cohort {#s3a}
--------------------------------

After removing outliers, a total of 40 resection specimens were assessed, including three major IPMN subtypes: pancreaticobiliary (n = 6), gastric (n = 30), and intestinal (n = 4). Five of the resection specimens had concomitant invasive adenocarcinoma (pancreaticobiliary (n = 2), gastric (n = 2), and intestinal (n = 1) subtypes). No oncocytic subtypes were identified in this study.

Correlation studies: CEA and histopathologic variables {#s3b}
------------------------------------------------------

Amongst the IPMN subtypes, the intestinal subtype had the largest median cyst fluid CEA level (median: 914.50 ng/mL; mean: 1268.00 ± 403.21 ng/mL), followed by pancreaticobiliary subtype (median: 207.00 ng/mL; mean: 381.28 ± 223.90 ng/mL) and gastric subtype (median: 193.00 ng/mL; mean: 368.99 ± 65.91 ng/mL) ([Fig. 2a](#F2){ref-type="fig"}). In addition, there was a statistically significant correlation between pre-operative cyst fluid CEA level and the intensity of luminal CEA staining (Pearson r = 0.611; P = 0.00003) ([Fig. 2b](#F2){ref-type="fig"}, [Table 1](#T1){ref-type="table"}). However, no correlation between pre-operative cyst fluid CEA level and CEA IHC staining within cystic mucinous secretions or mucinous epithelial cytoplasm was identified ([Table 1](#T1){ref-type="table"}). Similarly, there was no correlation between pre-operative cyst fluid CEA level and other IHC markers (MUC1, 2, 5, or 6) ([Table 2](#T2){ref-type="table"}), size of lesion ([Fig. 3](#F3){ref-type="fig"}, [Table 3](#T3){ref-type="table"}), grade of dysplasia, or presence of invasive carcinoma ([Table 3](#T3){ref-type="table"}). As expected, no staining for CEA-P was identified within the four cases of serous cystadenoma. Pre-operative pancreatic cyst CEA was neither sensitive nor specific for the presence of invasive carcinoma, with an area under the curve of 0.449 ([Fig. 4](#F4){ref-type="fig"}). Intensity of CDX2 nuclear staining correlated with pre-operative cyst fluid CEA (Pearson r = 0.343; P = 0.03) ([Table 3](#T3){ref-type="table"}).

![(a) Box and whisker plot of pre-operative IPMN cyst fluid CEA level (ng/mL) vs. IPMN subtypes. (b) Box and whisker plot of pre-operative IPMN cyst fluid CEA level (ng/mL) vs. CEA luminal staining assessed by immunohistochemistry of resected IPMNs.](gr-12-185-g002){#F2}

###### Pearson Correlation Between Pre-Operative Pancreatic Cyst Fluid CEA Level and CEA Immunohistochemical Staining Intensity

                                               CEA level
  ---------------------- --------------------- -----------
  CEA-P-IPMN lumenal     Pearson correlation   0.611
                         Sig. (two-tailed)     0.000\*
                         N                     40
  CEA-P-IPMN cytoplasm   Pearson correlation   0.099
                         Sig. (two-tailed)     0.541
                         N                     40
  CEA-P-IPMN secretion   Pearson correlation   0.028
                         Sig. (two-tailed)     0.861
                         N                     40

\*Correlation is significant at the 0.05 level (two-tailed).

###### Pearson Correlation Between Pre-Operative Pancreatic Cyst Fluid CEA Level and MUC1, MUC2, MUC5, MUC6 Immunohistochemical Staining Intensity

                                              CEA level
  --------------------- --------------------- -----------
  MUC1-IPMN lumenal     Pearson correlation   -0.137
                        Sig. (two-tailed)     0.477
                        N                     29
  MUC1-IPMN cytoplasm   Pearson correlation   -0.103
                        Sig. (two-tailed)     0.594
                        N                     29
  MUC1-IPMN secretion   Pearson correlation   -0.076
                        Sig. (two-tailed)     0.696
                        N                     29
  MUC2-pancrease        Pearson correlation   -0.082
                        Sig. (two-tailed)     0.616
                        N                     40
  MUC2-IPMN cytoplasm   Pearson correlation   0.259
                        Sig. (two-tailed)     0.107
                        N                     40
  MUC5-IPMN lumenal     Pearson correlation   0.000
                        Sig. (two-tailed)     0.998
                        N                     40
  MUC5-IPMN cytoplasm   Pearson correlation   -0.039
                        Sig. (two-tailed)     0.812
                        N                     40
  MUC5-IPMN secretion   Pearson correlation   0.038
                        Sig. (two-tailed)     0.818
                        N                     40
  MUC6-IPMN lumenal     Pearson correlation   -0.126
                        Sig. (two-tailed)     0.507
                        N                     30
  MUC6-IPMN cytoplasm   Pearson correlation   0.259
                        Sig. (two-tailed)     0.167
                        N                     30
  MUC6-IPMN secretion   Pearson correlation   -0.174
                        Sig. (two-tailed)     0.357
                        N                     30
  MUC6-pancrease        Pearson correlation   -0.105
                        Sig. (two-tailed)     0.582
                        N                     30

![Pre-operative pancreatic cyst fluid CEA level and corresponding tumor size (cm).](gr-12-185-g003){#F3}

###### Pearson Correlation Between Pre-Operative Pancreatic Cyst Fluid CEA Level and Tumor Size, Presence of Invasive Carcinoma and CDX2 Nuclear Staining Within IPMNs

                                          CEA level
  ----------------- --------------------- -----------
  Tumor size (cm)   Pearson correlation   -0.015
                    Sig. (two-tailed)     0.930
                    N                     38
  Carcinoma         Pearson correlation   0.070
                    Sig. (two-tailed)     0.668
                    N                     40
  CDX2-nuclear      Pearson correlation   0.343\*
                    Sig. (two-tailed)     0.030
                    N                     40

\*Correlation is significant at the 0.05 level (two-tailed).

![Receiver operator characteristic (ROC) curve of pre-operative CEA cyst fluid level for invasive carcinoma.](gr-12-185-g004){#F4}

Discussion {#s4}
==========

Pancreatic cyst lesions are frequently found incidentally during abdominal imaging for non-pancreatic symptomatology, comprising approximately 2.4-13.5% of patients with no history of pancreatic disease \[[@R19], [@R20]\]. The rate of pancreatic cyst disease appears to increase with age with several imaging and autopsy studies show an increased prevalence after the age of 70 years \[[@R20], [@R21]\]. Management for pancreatic cystic lesions depends on the risk of malignancy and/or progression towards invasive carcinoma. Generally, pancreatic cysts can be broadly categorized as neoplastic or non-neoplastic. Neoplastic cysts are further broadly classified as mucinous and nonmucinous cysts \[[@R22]\].

CEA is a useful biomarker for helping to distinguish mucinous from non-mucinous pancreatic cysts. In this study, pre-operative pancreatic cyst fluid CEA level positively correlated with the intensity of luminal CEA staining in the neoplastic epithelium lining the pancreatic cysts; this is consistent with prior studies suggesting that CEA is primarily expressed on the apical surface of the gastrointestinal epithelium \[[@R23]\]. Interestingly, we did not find association of pre-operative cyst CEA levels with CEA immunointensity in cyst secretion. It is possible there were pre-analytic variable that might impact immunointensity but not impact aspirate fluid measurements such as ischemia time and formalin fixation. It is also possible that CEA as mentioned earlier is expressed on the IPMN epithelial apical surface, may be more stable when it is cell bound rather than within secretions. The intestinal IPMN subtype had the highest cyst fluid CEA level, differing from prior studies suggesting gastric subtypes have the highest CEA levels \[[@R24]\]. Similar to what has been previously described in our study, there was no correlation between pre-operative cyst fluid CEA level and the presence of dysplasia or invasive carcinoma \[[@R18], [@R25]\]. Other molecular tools to help stratify pancreatic cysts based on malignancy are being explored, but their utility in routine clinical practice remains to be demonstrated \[[@R26]\].

Mucins are heavily glycosylated high molecular weight glycoproteins, which are linked to a protein backbone within epithelial cytoplasmic membranes via serine and threonine residues \[[@R27]\]. Immunohistochemical analysis for various mucin glycoproteins has revealed predictable patterns of mucin glycoprotein expression across both IPMN subtypes and within invasive pancreatic ductal adenocarcinoma \[[@R28]-[@R30]\]. MUC1 is a membrane associated mucin which has predominantly increased expression within pancreaticobiliary IPMN subtypes and is also over-expressed within invasive carcinoma. MUC2 is a gel forming mucin, which, along with CDX-2, is predominantly expressed within intestinal IPMN subtypes and rarely detected within invasive carcinoma. MUC5 and MUC6 are gel-forming mucins as well, which are expressed frequently within gastric, intestinal, and oncocytic IPMN subtypes, as well has frequently within invasive carcinoma \[[@R9], [@R31], [@R32]\]. In this study, no correlation was identified between mucin glycoprotein expression and pre-operative CEA levels, suggesting that although CEA is elevated within mucinous lesions, no discrete correlation was found to exist with the mucin glycoproteins analyzed.

One of the limitations of our study includes the absence of sufficiently available *KRAS* mutations status amongst our cases to compare pre-operative cyst fluid level with *KRAS* and *GNAS* mutation status. Also, the number of invasive adenocarcinoma (n = 5) in our cohort was limited and therefore may not be entirely representative of the relationship between pre-operative CEA level and presence of invasive carcinoma. Further, no oncocytic IPMN subtypes were identified in this study, thus a relationship between pre-operative cyst fluid CEA level and mucin glycoprotein expression could not be assessed in that particular subtype.

Although pre-operative CEA level remains one tool for assessing for the presence of mucinous cystic pancreatic lesions, this study attempts to highlight some of the challenges in its utility as a single marker of invasive carcinoma. In addition, to the best of our knowledge, this is the first study comparing mucin glycoprotein expression across subtypes of IPMN to cystic CEA level; and our result was that the mucin glycoprotein expression did not correlate with pre-operative cyst fluid CEA level. The rationale by using CEA levels for undertaking resection of a cystic lesion in pancreas needs to be evaluated more critically.
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